Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours – appraisal consultation document
In this DRAFT guidance, avapritinib is not recommended as cost-effectiveness estimates are higher than the range normally considered a cost-effective use of NHS resources and avapritinib does not meet the criteria to be included in the Cancer Drugs Fund.
Source:
National Institute for Health and Care Excellence